Is Wegovy or Ozempic Better for Weight Loss?

Last reviewed: July 8, 2026

Last updated: July 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy and Ozempic contain identical active pharmaceutical ingredients—semaglutide—yet patients often wonder which delivers better weight loss results. Clinical trials show semaglutide produces average weight loss of 15-22% of body weight over 68 weeks, with outcomes driven more by individual metabolism and adherence than brand name. PlexusDx provides compounded semaglutide injection from licensed 503A pharmacies, offering the same mechanism at a fraction of retail brand costs.

Wegovy vs. Ozempic: Understanding the Medication Difference

Wegovy and Ozempic are both semaglutide medications manufactured by Novo Nordisk, but they carry separate FDA approvals and distinct pricing structures. Wegovy received approval in 2021 specifically for chronic weight management in adults with obesity or overweight with weight-related conditions. Ozempic was approved in 2017 for type 2 diabetes blood sugar control. Despite identical chemical formulations, Wegovy costs significantly more—often $1,500+ per month with insurance or out-of-pocket—because it's marketed exclusively for weight loss.

The core mechanism remains unchanged between the two: semaglutide activates GLP-1 receptors in the brain and gut, reducing appetite, slowing gastric emptying, and improving blood sugar stability. This means a patient taking either medication experiences similar appetite suppression and metabolic shifts. The practical difference lies in dosing schedules and brand positioning rather than efficacy. Both require weekly injections and follow identical dose-escalation protocols over 16-20 weeks.

Clinical Weight Loss Results: What the Data Shows

The STEP trials, which evaluated Wegovy's effectiveness, documented an average weight loss of 15.3% at the 1.7 mg dose and 21.7% at the 2.4 mg dose over 68 weeks of treatment. Comparatively, patients on Ozempic for diabetes lose 2-3 kg more than placebo, but weight loss was not the primary trial endpoint. When semaglutide is used off-label for weight management at Wegovy doses, outcomes mirror the STEP data, confirming that the medication's weight loss benefit is dose-dependent and consistent across formulations.

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Cost Comparison: Brand Name vs. Compounded Semaglutide

Wegovy's retail price without insurance ranges from $1,350 to $1,550 per month, depending on the dose strength needed. Many insurance plans deny or limit coverage, citing weight loss as cosmetic rather than medically necessary. Ozempic's cost for weight management off-label typically mirrors Wegovy pricing, though it may be partially covered under diabetes plans for dual-indication patients. These costs create financial barriers for millions seeking evidence-based weight management.

PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan), flat-rate pricing that does not increase with dose escalation—your dose may need to go up, but your price won't. All PlexusDx medications are compounded by licensed 503A pharmacies, meet USP standards, and are available without insurance requirement in all 50 states. Patients save $1,000-$1,400 monthly compared to brand-name Wegovy while receiving the identical active medication through legitimate pharmaceutical channels.

Side Effects, Safety, and Who Should Choose Semaglutide

Both Wegovy and Ozempic carry similar adverse event profiles: nausea, vomiting, diarrhea, and constipation occur in 20-40% of users during the first 4-8 weeks as the dose escalates. These effects typically diminish as the body adapts. Rare but serious risks include acute kidney injury, pancreatitis, and gallbladder complications. Patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 should avoid semaglutide entirely.

Weight loss success with semaglutide requires sustained medication use; stopping treatment often results in weight regain within 6-12 months. Candidates benefit most from concurrent lifestyle modification—modest calorie reduction and regular physical activity amplify pharmaceutical effects. PlexusDx patients receive telehealth provider oversight, personalized dosing protocols, and genetic insights to optimize tolerability and efficacy before committing to long-term therapy.

Exploring Alternatives: Tirzepatide and Dual Compound Options

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, and GIPR — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

For patients seeking maximum potency, PlexusDx GLP-Squared Injection combines semaglutide and tirzepatide in a single compounded formulation at $289/mo month-to-month, or from $249/mo on the 6-month plan. This dual-compound approach activates three receptor pathways simultaneously (GLP1R, GIP, and additional metabolic signaling) and may benefit patients who plateau on monotherapy. Genetic testing through PlexusDx illuminates which compound strategy aligns with your individual peptide-pathway biology.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is Wegovy actually better than Ozempic for weight loss?

No—Wegovy and Ozempic contain identical semaglutide and produce equivalent weight loss when dosed identically. The difference is marketing and pricing. Wegovy costs $1,500+ monthly because it's branded for weight loss, while Ozempic costs slightly less despite being the same medication. PlexusDx compounded semaglutide delivers the same mechanism at $189/month.

How much weight will I lose on semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to Ozempic or any specific medication. It analyzes pathway-level variants (GLP1R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Why is PlexusDx semaglutide so much cheaper than Wegovy?

PlexusDx sources semaglutide from licensed 503A compounding pharmacies, eliminating brand manufacturing and marketing overhead. Wegovy's $1,500+ price includes brand premium, distribution margins, and patent protections. Both are legitimate pharmaceutical-grade products; PlexusDx simply removes middlemen. Your dose may need to go up—your price won't ($189/mo flat).

What are the main side effects, and how long do they last?

Nausea, vomiting, diarrhea, and constipation affect 20-40% of users, typically during the first 4-8 weeks. Side effects usually resolve as your body adapts. Serious risks (pancreatitis, kidney injury, gallbladder issues) are rare but require immediate medical attention. PlexusDx providers monitor safety throughout treatment and adjust dosing if side effects persist.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R (rs6923761)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Wegovy For Weight Loss 2
• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Wegovy Weight Loss Pills

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.